Is WuXi Bio (2269) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.3% / 30% | 7.1% / 30% | 3.7% / 30% | 1.88% / 5% | ✓ HALAL |
| DJIM | 3.3% / 33% | 7.1% / 33% | 3.7% / 33% | 1.88% / 5% | ✓ HALAL |
| MSCI | 8.7% / 33% | 18.8% / 33% | 9.7% / 33% | 1.88% / 5% | ✓ HALAL |
| S&P | 3.3% / 33% | 7.1% / 33% | 3.7% / 33% | 1.88% / 5% | ✓ HALAL |
| FTSE | 8.7% / 33% | 18.8% / 33% | 9.7% / 50% | 1.88% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 46.0% | |
| Operating Margin | 33.1% | |
| Net Margin | 22.5% | |
| Return on Equity (ROE) | 11.6% | |
| Return on Assets (ROA) | 6.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $5.2B |
| Free Cash Flow | $1.3B |
| Total Debt | $4.9B |
| Debt-to-Equity | 5.9 |
| Current Ratio | 3.4 |
| Total Assets | $57.0B |
Price & Trading
| Last Close | HKD 31.54 |
| 50-Day MA | HKD 37.37 |
| 200-Day MA | HKD 34.20 |
| Avg Volume | 33.7M |
| Beta | 0.5 |
|
52-Week Range
HKD 16.20
| |
About WuXi Bio (2269)
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. It has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company has a strategic collaboration with Sinorda Biomedicine Ltd. for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Purification Calculator
As a halal stock with 1.88% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is WuXi Bio (2269) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), WuXi Bio is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is WuXi Bio's debt ratio?
WuXi Bio's debt ratio is 3.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.7%.
Does WuXi Bio require dividend purification?
Yes, WuXi Bio has an impermissible income ratio of 1.88%, which means 1.88% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are WuXi Bio's key financial metrics?
WuXi Bio has a market capitalization of $133.8B, trailing P/E ratio of 24.7, and revenue of $18.7B. The company maintains a gross margin of 46.0% and a net margin of 22.5%. Return on equity stands at 11.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.